Perioperative Chemotherapy Improves Overall Survival in Synchronous Colorectal Liver Metastases

Analyzing 72,376 patients with colorectal liver metastases (CRLM) from the National Cancer Database, researchers found that liver-only CRLM patients undergoing perioperative chemotherapy had a superior median overall survival (OS) of 44.7 months. Resection of both primary and metastatic sites also correlated with better OS (38.9 months) compared to metastatic site alone (30.2 months) or primary tumor alone (22.3 months). These findings support combining resection with perioperative systemic therapy for improved outcomes in CRLM patients.